thèse de Sandrine Roux

Daptomycin does not have approval for the treatment of bone and joint infections (BJI). The Infectious Diseases Society of America guidelines propose daptomycin 6 mg/kg/d as alternative therapy for prosthetic joint infection, whereas recent data support the use of higher doses in these patients. Between 2010 and 2013, consecutive patients receiving daptomycin >6 mg/kg/d for complex BJI were included in